Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02516150 · ClinicalTrials.gov registry record · Phase 4
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
A Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT02516150: Completed Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Massachusetts General Hospital.
NCT02516150 is a Phase 4 study of Type 1 Diabetes Mellitus that has completed, run by Massachusetts General Hospital. The registered enrollment target is 26 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02516150, a Phase 4 study of Type 1 Diabetes Mellitus, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
Primary Outcome
Area over the curve for the glucose infusion rate in the hour following a subcutaneous glucagon dose with a blood alcohol content of 0 vs 0.1%
Conditions Studied
Interventions
- DRUG Ethanol
- DRUG Glucagon
Study Locations (1)
Massachusetts
- Massachusetts General Hospital Diabetes Research Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
What the finished NCT02516150 record still lists
NCT02516150 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Ethanol is the first listed.
NCT02516150 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02516150 about?
NCT02516150 is a clinical study titled "Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon". This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
What is the current status of trial NCT02516150?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2016-03. Estimated completion is 2017-06.
What conditions does trial NCT02516150 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT02516150?
The interventions under investigation include: Ethanol (DRUG), Glucagon (DRUG).
Who is sponsoring clinical trial NCT02516150?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02516150 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02516150's enrollment target sits among peer trials
26 81st of 112 higher than 32 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 4
-
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
COMPLETED · Phase 4
-
Detemir: Role in Type 1 Diabetes
COMPLETED · Phase 4
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia